Frailty is associated with poor mental health 1 year after hospitalisation with COVID-19.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 08 2022
Historique:
received: 30 01 2022
revised: 09 04 2022
accepted: 05 05 2022
pubmed: 15 5 2022
medline: 9 6 2022
entrez: 14 5 2022
Statut: ppublish

Résumé

Frailty is associated with long-term physical deterioration after COVID-19. Mental health recovery has been less well investigated. Early studies have shown minimal effect from the virus, although studies have not focused on whether people living with frailty may have different psychiatric outcomes. We aimed to examine the effect of living with frailty on mental health outcomes one year after hospital with COVID-19. We undertook a multicentre cross-sectional study of people admitted with COVID-19. We assessed quality of life (ICECAP-O and MRC), psychiatric symptoms including: generalised anxiety (GAD-7), depression (Patient Health Questionnaire-9), and trauma (Trauma Screening Questionnaire). Frailty was measured using the Clinical Frailty Scale (CFS). We used a multivariable mixed-effects logistic and linear regression to examine the adjusted odds ratio (aOR) and adjusted mean difference (aMD). From eight hospitals 224 participants consented. Median follow-up time from admission 358 days (IQR 153-418), mean age 63.8 (SD = 13.7), 34.8% female (n = 78), and 43.7% living with frailty (n = 98 CFS 4-8). People living with frailty were significantly more likely to have symptoms of anxiety aOR = 5.72 (95% CI 1.71-19.13), depression aOR = 2.52 (95% CI 1.59-14.91), post-traumatic stress disorder aMD = 1.16 (95% CI 0.47, 1.85), and worse quality of life aMD = 1.06 (95% CI 0.76-1.36). Patient-rated symptoms were captured rather than formal mental health diagnoses. CFS has not been validated in under 65-year-olds. Living with frailty is associated with significant psychiatric morbidity and reduced wellbeing one year after COVID-19 hospital admission. We recommend clinical follow-up after COVID-19 for people living with frailty should include a psychiatric assessment.

Sections du résumé

BACKGROUND
Frailty is associated with long-term physical deterioration after COVID-19. Mental health recovery has been less well investigated. Early studies have shown minimal effect from the virus, although studies have not focused on whether people living with frailty may have different psychiatric outcomes. We aimed to examine the effect of living with frailty on mental health outcomes one year after hospital with COVID-19.
METHODS
We undertook a multicentre cross-sectional study of people admitted with COVID-19. We assessed quality of life (ICECAP-O and MRC), psychiatric symptoms including: generalised anxiety (GAD-7), depression (Patient Health Questionnaire-9), and trauma (Trauma Screening Questionnaire). Frailty was measured using the Clinical Frailty Scale (CFS). We used a multivariable mixed-effects logistic and linear regression to examine the adjusted odds ratio (aOR) and adjusted mean difference (aMD).
RESULTS
From eight hospitals 224 participants consented. Median follow-up time from admission 358 days (IQR 153-418), mean age 63.8 (SD = 13.7), 34.8% female (n = 78), and 43.7% living with frailty (n = 98 CFS 4-8). People living with frailty were significantly more likely to have symptoms of anxiety aOR = 5.72 (95% CI 1.71-19.13), depression aOR = 2.52 (95% CI 1.59-14.91), post-traumatic stress disorder aMD = 1.16 (95% CI 0.47, 1.85), and worse quality of life aMD = 1.06 (95% CI 0.76-1.36).
LIMITATIONS
Patient-rated symptoms were captured rather than formal mental health diagnoses. CFS has not been validated in under 65-year-olds.
CONCLUSIONS
Living with frailty is associated with significant psychiatric morbidity and reduced wellbeing one year after COVID-19 hospital admission. We recommend clinical follow-up after COVID-19 for people living with frailty should include a psychiatric assessment.

Identifiants

pubmed: 35568322
pii: S0165-0327(22)00538-9
doi: 10.1016/j.jad.2022.05.035
pmc: PMC9091159
pii:
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

377-383

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Références

Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Lancet. 2013 Mar 2;381(9868):752-62
pubmed: 23395245
J Frailty Aging. 2017;6(4):219-223
pubmed: 29165541
J Am Med Dir Assoc. 2016 May 1;17(5):448-50
pubmed: 26994856
Eur J Intern Med. 2016 Nov;35:24-34
pubmed: 27596721
Intensive Care Med. 2017 Aug;43(8):1105-1122
pubmed: 28676896
Ann Surg. 2021 Apr 1;273(4):709-718
pubmed: 31188201
Age Ageing. 2019 Nov 1;48(6):922-926
pubmed: 31566668
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Lancet Public Health. 2018 Jul;3(7):e323-e332
pubmed: 29908859
Lancet. 2018 May 5;391(10132):1775-1782
pubmed: 29706364
Age Ageing. 2019 May 1;48(3):388-394
pubmed: 30778528
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076

Auteurs

Philip Braude (P)

CLARITY (Collaborative Ageing Research) Group, NHS, Bristol, UK. Electronic address: philip.braude@nbt.nhs.uk.

Kathryn McCarthy (K)

CLARITY (Collaborative Ageing Research) Group, NHS, Bristol, UK.

Rebecca Strawbridge (R)

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, PO74, King's College London, De Crespigny Park, London SE5 8AZ, UK; National Institute for Health Research Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London SE5 8AZ, UK.

Roxanna Short (R)

CLARITY (Collaborative Ageing Research) Group, NHS, Bristol, UK; Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

Alessia Verduri (A)

University of Modena and Reggio Emilia - Hospital Policlinico Modena, Italy.

Arturo Vilches-Moraga (A)

Salford Royal NHS Trust, Salford, UK.

Jonathan Hewitt (J)

Cardiff University, Cardiff, Wales, UK.

Ben Carter (B)

CLARITY (Collaborative Ageing Research) Group, NHS, Bristol, UK; Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH